In the second quarter of fiscal 2025, sales in the Natural segment grew 8.2%. New UpgradesImproving Clearing and Transaction Fees Aid CME Group (CME) Per the Zacks analyst, CME Group is set to grow on higher clearing and transaction fees as market position, diverse derivative product lines and expansion of futures products drive volumes.Telefonica (TEF) Gains on Service Growth, AI & 5G ExpansionPer the Zacks analyst, robust B2B and B2C demand, AI-led innovation and 5G rollout fuel Telefonica's growth, with Tech unit gains in cybersecurity and IoT boosting long-term prospects.AngioDynamics (ANGO) Gains on NanoKnife Tech, Cancer FocusPer the Zacks analyst, AngioDynamics is gaining from NanoKnife prospects and a deeper focus on pancreatic cancer. A strong product portfolio further supports growth and boosts investor confidence.New DowngradesAgios' (AGIO) Sole Dependence on Pyrukynd A ConcernPer the Zacks Analyst, Agios is highly dependent on its sole marketed drug, Pyrukynd, to drive sales.